Drug intelligence / Profile preview

Lactobacillus plantarum MTCC1325

Development stage: Preclinical
Lead developer: MTCC
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus plantarum MTCC1325 is a specific probiotic strain of *Lactobacillus plantarum* that has demonstrated anti-Alzheimer properties in preclinical studies using albino rats. Isolated from sauerkraut, this strain exerts its therapeutic effects by producing the neurotransmitter acetylcholine, exhibiting significant antioxidant activity, and modulating membrane-bound transport ATPases. These actions collectively contribute to its beneficial impact on cognitive function and neurodegeneration, primarily through its influence on the gut-brain axis. It is being investigated for its potential in treating cognitive disorders like Alzheimer's disease.

Other names: L. plantarum MTCC1325

Targets

AcetylcholinesteraseATP2A (Sarcoplasmic reticulum Ca2+-ATPase)

Beyond the preview

Go deeper on Lactobacillus plantarum MTCC1325.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus plantarum MTCC1325.

Explore the full profile